JP7534293B2 - 放射線誘発肺障害のためのバイオマーカー及び使用方法 - Google Patents

放射線誘発肺障害のためのバイオマーカー及び使用方法 Download PDF

Info

Publication number
JP7534293B2
JP7534293B2 JP2021523754A JP2021523754A JP7534293B2 JP 7534293 B2 JP7534293 B2 JP 7534293B2 JP 2021523754 A JP2021523754 A JP 2021523754A JP 2021523754 A JP2021523754 A JP 2021523754A JP 7534293 B2 JP7534293 B2 JP 7534293B2
Authority
JP
Japan
Prior art keywords
nampt
rili
subject
tissue
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021523754A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509018A (ja
JP2022509018A5 (enExample
Inventor
ジー．エヌ．ガルシア ジョー
Original Assignee
アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ filed Critical アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ
Publication of JP2022509018A publication Critical patent/JP2022509018A/ja
Publication of JP2022509018A5 publication Critical patent/JP2022509018A5/ja
Application granted granted Critical
Publication of JP7534293B2 publication Critical patent/JP7534293B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/02012—Nicotinamide phosphoribosyltransferase (2.4.2.12), i.e. visfatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/40—Disorders due to exposure to physical agents, e.g. heat disorders, motion sickness, radiation injuries, altitude sickness, decompression illness
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2021523754A 2018-10-31 2019-10-31 放射線誘発肺障害のためのバイオマーカー及び使用方法 Active JP7534293B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862753802P 2018-10-31 2018-10-31
US62/753,802 2018-10-31
US201962896483P 2019-09-05 2019-09-05
US62/896,483 2019-09-05
PCT/IB2019/059379 WO2020089841A1 (en) 2018-10-31 2019-10-31 Biomarkers and methods of use for radiation-induced lung injury

Publications (3)

Publication Number Publication Date
JP2022509018A JP2022509018A (ja) 2022-01-20
JP2022509018A5 JP2022509018A5 (enExample) 2022-11-08
JP7534293B2 true JP7534293B2 (ja) 2024-08-14

Family

ID=68542675

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523754A Active JP7534293B2 (ja) 2018-10-31 2019-10-31 放射線誘発肺障害のためのバイオマーカー及び使用方法

Country Status (8)

Country Link
US (2) US11733242B2 (enExample)
EP (2) EP3874273B1 (enExample)
JP (1) JP7534293B2 (enExample)
CN (1) CN113614535B (enExample)
AU (1) AU2019371161A1 (enExample)
CA (1) CA3117112A1 (enExample)
ES (1) ES2975662T3 (enExample)
WO (1) WO2020089841A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220403412A1 (en) * 2021-06-11 2022-12-22 Hui JING Baculovirus Of Recombinant Superoxide Dismutase Gene, Preparation And Application Thereof
CN114578058A (zh) * 2022-02-09 2022-06-03 中国人民解放军军事科学院军事医学研究院 一种放射损伤标志物bpifa2的应用及其相关试剂盒及试剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011109650A1 (en) 2010-03-03 2011-09-09 The Board Of Trustees Of The University Of Illinois Method of treating acute lung injury using sphingosine 1 phosphate analoges or sphingosine 1 phosphate receptor agonists
JP2016101161A (ja) 2014-11-14 2016-06-02 東芝メディカルシステムズ株式会社 被検細胞の細胞特性を評価するための遺伝子マーカー、方法、レポーターベクター、プライマーセットおよびアッセイキット、並びに細胞特性評価装置
WO2017041114A2 (en) 2015-09-03 2017-03-09 The Children's Mercy Hospital Anti-nicotinamide phosphoribosyltransferase antibody genes and methods of use thereof
WO2018191751A1 (en) 2017-04-14 2018-10-18 Arizona Board Of Regents On Behalf Of The University Of Arizonia Compositions and methods for treating pulmonary fibrosis

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4415723A (en) 1982-03-19 1983-11-15 General Electric Company Randomly branched aromatic polycarbonate from triphenol
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
ATE88761T1 (de) 1986-01-10 1993-05-15 Amoco Corp Kompetitiver homogener test.
IL86724A (en) 1987-06-19 1995-01-24 Siska Diagnostics Inc Methods and kits for amplification and testing of nucleic acid sequences
ATE92538T1 (de) 1988-01-21 1993-08-15 Genentech Inc Verstaerkung und nachweis von nukleinsaeuresequenzen.
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5932413A (en) 1988-04-01 1999-08-03 Celebuski; Joseph Eugene DNA probe assay using neutrally charged probe strands
US5187260A (en) 1988-09-06 1993-02-16 Sharifa Karali Process for the preparation of a high purity protamine-DNA complex and process for use of same
US5856092A (en) 1989-02-13 1999-01-05 Geneco Pty Ltd Detection of a nucleic acid sequence or a change therein
US5075212A (en) 1989-03-27 1991-12-24 University Of Patents, Inc. Methods of detecting picornaviruses in biological fluids and tissues
US5849481A (en) 1990-07-27 1998-12-15 Chiron Corporation Nucleic acid hybridization assays employing large comb-type branched polynucleotides
US5645987A (en) 1990-09-21 1997-07-08 Amgen Inc. Enzymatic synthesis of oligonucleotides
US5846717A (en) 1996-01-24 1998-12-08 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US5849486A (en) 1993-11-01 1998-12-15 Nanogen, Inc. Methods for hybridization analysis utilizing electrically controlled hybridization
US5846708A (en) 1991-11-19 1998-12-08 Massachusetts Institiute Of Technology Optical and electrical methods and apparatus for molecule detection
FR2685346B1 (fr) 1991-12-18 1994-02-11 Cis Bio International Procede de preparation d'arn double-brin, et ses applications.
JP3633932B2 (ja) 1992-04-01 2005-03-30 ザ ジョーンズ ホプキンズ ユニバーシティー スクール オブ メディシン 糞便試料から単離した哺乳類の核酸を検出する方法、およびその検出用試薬
US5843640A (en) 1992-06-19 1998-12-01 Northwestern University Method of simultaneously detecting amplified nucleic acid sequences and cellular antigens in cells
US5861244A (en) 1992-10-29 1999-01-19 Profile Diagnostic Sciences, Inc. Genetic sequence assay using DNA triple strand formation
US5658751A (en) 1993-04-13 1997-08-19 Molecular Probes, Inc. Substituted unsymmetrical cyanine dyes with selected permeability
US5279721A (en) 1993-04-22 1994-01-18 Peter Schmid Apparatus and method for an automated electrophoresis system
GB9311386D0 (en) 1993-06-02 1993-07-21 Pna Diagnostics As Nucleic acid analogue assay procedures
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
GB2284208A (en) 1993-11-25 1995-05-31 Pna Diagnostics As Nucleic acid analogues with a chelating functionality for metal ions
DE69432919T2 (de) 1993-12-28 2004-05-27 Tanabe Seiyaku Co., Ltd. Verfahren für den Nachweis spezifischer Polynukleotiden
US5599668A (en) 1994-09-22 1997-02-04 Abbott Laboratories Light scattering optical waveguide method for detecting specific binding events
DE69535240T2 (de) 1994-10-28 2007-06-06 Gen-Probe Inc., San Diego Zusammensetzungen und Verfahren für die gleichzeitige Detektion und Quantifizierung von einer Mehrheit spezifischer Nuklein Säure Sequenzen
US5889136A (en) 1995-06-09 1999-03-30 The Regents Of The University Of Colorado Orthoester protecting groups in RNA synthesis
US5929227A (en) 1995-07-12 1999-07-27 The Regents Of The University Of California Dimeric fluorescent energy transfer dyes comprising asymmetric cyanine azole-indolenine chromophores
US5916779A (en) 1995-09-21 1999-06-29 Becton, Dickinson And Company Strand displacement amplification of RNA targets
US5866331A (en) 1995-10-20 1999-02-02 University Of Massachusetts Single molecule detection by in situ hybridization
US5851772A (en) 1996-01-29 1998-12-22 University Of Chicago Microchip method for the enrichment of specific DNA sequences
US5912124A (en) 1996-06-14 1999-06-15 Sarnoff Corporation Padlock probe detection
US5853990A (en) 1996-07-26 1998-12-29 Edward E. Winger Real time homogeneous nucleotide assay
US6413544B1 (en) 1996-08-19 2002-07-02 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
US5853992A (en) 1996-10-04 1998-12-29 The Regents Of The University Of California Cyanine dyes with high-absorbance cross section as donor chromophores in energy transfer labels
US5853993A (en) 1996-10-21 1998-12-29 Hewlett-Packard Company Signal enhancement method and kit
US5900481A (en) 1996-11-06 1999-05-04 Sequenom, Inc. Bead linkers for immobilizing nucleic acids to solid supports
US5905024A (en) 1996-12-17 1999-05-18 University Of Chicago Method for performing site-specific affinity fractionation for use in DNA sequencing
US5846729A (en) 1997-02-27 1998-12-08 Lorne Park Research, Inc. Assaying nucleotides in solution using a fluorescent intensity quenching effect
US5846726A (en) 1997-05-13 1998-12-08 Becton, Dickinson And Company Detection of nucleic acids by fluorescence quenching
US5928869A (en) 1997-05-30 1999-07-27 Becton, Dickinson And Company Detection of nucleic acids by fluorescence quenching
US5919626A (en) 1997-06-06 1999-07-06 Orchid Bio Computer, Inc. Attachment of unmodified nucleic acids to silanized solid phase surfaces
US5935791A (en) 1997-09-23 1999-08-10 Becton, Dickinson And Company Detection of nucleic acids by fluorescence quenching
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2361201A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
ES2220522T3 (es) 1999-08-18 2004-12-16 Ramot At Tel-Aviv University Ltd. Peptidos oralmente activos que evitan el daño y la muerte celular.
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
WO2002100325A2 (en) 2000-10-13 2002-12-19 Ligocyte Pharmaceuticals, Inc. Polyvalent nanoparticles
JP2005511761A (ja) 2001-07-10 2005-04-28 ノース・キャロライナ・ステイト・ユニヴァーシティ ナノ粒子送達ビヒクル
US20050143336A1 (en) 2003-12-30 2005-06-30 Board Of Regents, The University Of Texas System Methods and compositions for improved non-viral gene therapy
US9409983B2 (en) 2009-07-23 2016-08-09 The Board Of Trustess Of The University Of Illinois Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
CN103961691A (zh) * 2013-02-03 2014-08-06 复旦大学 尼克酰胺磷酸核糖转移酶在制备神经保护药物中的用途
ITTO20130356A1 (it) * 2013-05-03 2014-11-04 Uni Degli Studi Del Piemonte Orientale Ame Inibitori di nicotinamide fosforibosil transferasi, relative composizioni, prodotti ed usi
WO2018191747A1 (en) 2017-04-14 2018-10-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating pulmonary arterial hypertension
CA3147020A1 (en) 2019-08-07 2021-02-11 Joe G.N. Garcia Anti-nampt antibodies and uses thereof
EP4010486A4 (en) 2019-08-07 2023-11-01 Arizona Board of Regents on behalf of the University of Arizona MONONUCLEOTIDE POLYMORPHISMS AND THEIR USES
CA3188685A1 (en) 2020-08-07 2022-02-10 Joe G.N. Garcia Single nucleotide polymorphisms and treatment of inflammatory conditions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011109650A1 (en) 2010-03-03 2011-09-09 The Board Of Trustees Of The University Of Illinois Method of treating acute lung injury using sphingosine 1 phosphate analoges or sphingosine 1 phosphate receptor agonists
JP2016101161A (ja) 2014-11-14 2016-06-02 東芝メディカルシステムズ株式会社 被検細胞の細胞特性を評価するための遺伝子マーカー、方法、レポーターベクター、プライマーセットおよびアッセイキット、並びに細胞特性評価装置
WO2017041114A2 (en) 2015-09-03 2017-03-09 The Children's Mercy Hospital Anti-nicotinamide phosphoribosyltransferase antibody genes and methods of use thereof
WO2018191751A1 (en) 2017-04-14 2018-10-18 Arizona Board Of Regents On Behalf Of The University Of Arizonia Compositions and methods for treating pulmonary fibrosis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bin Xiang, Lichi Han, Xinyue Wang, Ling Tang, Kailiang Li, Xiuxiu Li, Xibo Zhao, Miaomiao Xia, Xixi Zhou, Fuyin Zhang, Ke Jian Liu,，Nicotinamide Phosphoribosyltransferase Upregulation by Phenylephrine Reduces Radiation Injury in Submandibular Gland,，International Journal of Radiation Oncology*Biology*Physics,，2016年11月01日，Volume 96, Issue 3,，Pages 538-546,，https://doi.org/10.1016/j.ijrobp.2016.06.2442.
Shui Q. Ye, Brett A. Simon, James P. Maloney, April Zambelli-Weiner, Li Gao, Audrey Grant, R. Blaine Easley, Bryan J. McVerry, Rubin M. Tuder, Theodore Standiford, Roy G. Brower, Kathleen C. Barnes, and Joe G. N. Garcia，Pre-B-Cell Colony-enhancing Factor as a Potential Novel Biomarker in Acute Lung Injury，Am J Respir Crit Care Med，2004年12月03日，Vol 171.，pp 361-370,，DOI: 10.1164/rccm.200404-563OC
Xu-Wei Cai, Kerby A. Shedden, Shang-Hu Yuan, Mary A. Davis, Lu-Ying Xu, Cong-Ying Xie, Xiao-Long Fu, Theodore S. Lawrence, David M. Lubman, Feng-Ming (Spring) Kong,，Baseline Plasma Proteomic Analysis to Identify Biomarkers that Predict Radiation-Induced Lung Toxicity in Patients Receiving Radiation for Non-small Cell Lung Cancer,，Journal of Thoracic Oncology,，2011年06月，Volume 6, Issue 6,，Pages 1073-1078,，https://doi.org/10.1097/JTO.0b013e3182152ba6.

Also Published As

Publication number Publication date
EP3874273B1 (en) 2024-03-27
EP3874273A1 (en) 2021-09-08
JP2022509018A (ja) 2022-01-20
AU2019371161A1 (en) 2021-06-17
EP4439066A2 (en) 2024-10-02
CN113614535B (zh) 2024-08-16
ES2975662T3 (es) 2024-07-11
US11733242B2 (en) 2023-08-22
WO2020089841A1 (en) 2020-05-07
CN113614535A (zh) 2021-11-05
US20240085422A1 (en) 2024-03-14
EP3874273C0 (en) 2024-03-27
CA3117112A1 (en) 2020-05-07
US20200132689A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
DK2859120T3 (en) Method for diagnosis and prognosis of lung cancer metastasis
KR102442275B1 (ko) 암 전이의 예후 및 치료 방법
EP2300041B1 (en) Method for determining risk of recurrence of prostate cancer
DK3055429T3 (en) Procedure for the prognosis and treatment of metastatic bone cancer resulting from breast cancer
JP6636067B2 (ja) ｃ−ＭＡＦを用いた前立腺がん転移の診断、予後診断および処置のための方法
JP5750433B2 (ja) 診断および治療のための腫瘍関連抗原の同定
KR20150122731A (ko) 암 전이의 예후 및 치료 방법
US20240085422A1 (en) Biomarkers and methods of use for radiation-induced lung injury
JP2015518367A (ja) 腸透過性のｅｇｆｒおよびｐａｒ２の調節
US20170269103A1 (en) Assessment of Heart Failure and Arrhythmic Risk Stratification by Measuring Circulating Hu Proteins
WO2007115068A2 (en) Genetic variants in the indoleamine 2,3-dioxygenase gene
Tsuiki et al. Single nucleotide polymorphism 309 affects murin-double-minute 2 protein expression but not glioma tumorigenesis
JPWO2009017052A1 (ja) 変形性関節症感受性遺伝子
JPWO2005021739A1 (ja) Ｎｏｘ１ポリペプチドに対する抗体、Ｎｏｘ１遺伝子を利用したガン診断方法、及びガン増殖抑制物質のスクリーニング方法
MX2008003464A (en) Identification of tumor-associated antigens for diagnosis and therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221028

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240605

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240702

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240801

R150 Certificate of patent or registration of utility model

Ref document number: 7534293

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150